These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29687693)

  • 41. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survey on the Adherence to the 2009 NASPGHAN-ESPGHAN Gastroesophageal Reflux Guidelines by Brazilian Paediatricians.
    Vieira SCF; Gurgel FM; Leão MZ; Costa-Silva TE; Barreto IDC; Martins-Filho PRS; Vieira MC; Gurgel RQ
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):e1-e5. PubMed ID: 29394212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective Study of Gastroesophageal Reflux, Use of Proton Pump Inhibitors and H2-Receptor Antagonists, and Risk of Hearing Loss.
    Lin BM; Curhan SG; Wang M; Jacobson BC; Eavey R; Stankovic KM; Curhan GC
    Ear Hear; 2017; 38(1):21-27. PubMed ID: 27556519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Numans ME; Bonis PA; Lau J
    Cochrane Database Syst Rev; 2000; (2):CD002095. PubMed ID: 10796857
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gastroesophageal reflux disease. The long and the short of therapeutic options.
    Brady WM; Ogorek CP
    Postgrad Med; 1996 Nov; 100(5):76-80, 85-6, 89. PubMed ID: 8917326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pancreatic Cancer Management and Treatment Landscape Awareness of Gastroenterologists: Results from US Physician Surveys Conducted in 2013 and 2015.
    Salinas GD; Whitworth L; Merwin P; Emarine J
    J Gastrointest Cancer; 2018 Mar; 49(1):41-49. PubMed ID: 28005258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging drugs for gastroesophageal reflux disease.
    Boeckxstaens GE
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):481-91. PubMed ID: 19650746
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gaviscon® Advance alone versus co-prescription of Gaviscon® Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux.
    Wilkie MD; Fraser HM; Raja H
    Eur Arch Otorhinolaryngol; 2018 Oct; 275(10):2515-2521. PubMed ID: 30062580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. National Study of Off-label Proton Pump Inhibitor Use Among New Zealand Infants in the First Year of Life (2005-2012).
    Blank ML; Parkin L
    J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):179-184. PubMed ID: 28403034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastro-oesophageal reflux disease (GORD) in Australian general practice patients.
    Miller G; Wong C; Pollack A
    Aust Fam Physician; 2015 Oct; 44(10):701-4. PubMed ID: 26484482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
    Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
    World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
    Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of the ALEGRIA study in Luxembourg. An epidemiological, observational study to describe symptom impact and control in patients with GERD and an evaluation of the GERD Impact Scale.
    Fritz R; Goodman N; Duquenne V; Taeter C
    Bull Soc Sci Med Grand Duche Luxemb; 2009; (2):141-52. PubMed ID: 19999624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux.
    Palmieri B; Merighi A; Corbascio D; Rottigni V; Fistetto G; Esposito A
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3272-8. PubMed ID: 24379055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the impact of lifestyle modification education on knowledge and behavior changes in gastroesophageal reflux disease patients on proton pump inhibitors.
    Finley K; Giannamore M; Bennett M; Hall L
    J Am Pharm Assoc (2003); 2009; 49(4):544-8. PubMed ID: 19589767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unmet treatment needs of gastroesophageal reflux disease in Asia: gastroesophageal reflux disease in Asia Pacific survey.
    Goh KL; Choi MG; Hsu WP; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Chu R; Shetty V; Bocobo JC; Chan MM; Lin JT
    J Gastroenterol Hepatol; 2014 Dec; 29(12):1969-75. PubMed ID: 24990817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
    Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Scope of Pre- and Probiotics as an Add-on to Proton-pump Inhibitors in Various Clinical Indications.
    Kalra S; Joshi A; Tiwaskar M; Agrawal N; Shaikh S; Bhatia BS; Jhingan AK; Rawal P; Das AK; Nishad SK; Manjrekar H; Bhadury S
    J Assoc Physicians India; 2023 Dec; 71(12):28-31. PubMed ID: 38736051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.